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1. Introduction
Radiopharmaceuticals have been widely used in many clinical and nonclinical applications,
such as in vivo and non-invasive diagnosis or treatment of human diseases. The quality of
radiopharmaceuticals administered for a patient is primarily related for the radiation dose
delivered to achieve optimizing diagnostic imaging or therapeutic efficacy. Radiopharmaceut‐
icals with different half-lives (short, medium, and long), decay modes (alpha, beta, gamma,
and electron capture), and biochemical properties (of ligands) can determine their utilities in
medicine. Moreover, chemical and radiochemical impurities in a radiopharmaceutical can
produce a serious trouble of diagnosis or treatment. Therefore, different requirements, regu‐
lations, and instrumentations for ensuring their high quality and high safety have been devel‐
oped in many countries.
There are only few years for the progress of “Quality by Design (QbD)” in International
Conference on Harmonisation (ICH) Guidelines, e.g. ICH Q8, ICH Q9, and ICH Q10 [1-3].
According to the requirement of ICH Q8, quality can not be tested into products; i.e., quali‐
ty should be built in by design, i.e. QbD. Enhanced QbD approach to pharmaceutical devel‐
opment can improve the product and process knowledge.
In this chapter, we provide a harmonized framework of QbD for manufacturing and clini‐
cal applications of radiopharmaceuticals in accordance with the requirements and guide‐
lines of U.S. Food and Drug Administration (FDA), International Atomic Energy Agency
© 2012 Liu et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
(IAEA), World Health Organization (WHO) and European Association of Nuclear Medi‐
cine (EANM). The attributes of the components in the quality system (QA/QC), including
organization, staffing and personnel, facilities, instrumentation and equipment, operation
procedure, radiopharmaceuticals, protocol and conduct of a study or a treatment, records
and reports, and audit framework were further characterized. Assessments and compari‐
sons of critical quality attributes (CQAs) for assuring accurate radioactive dosimetry calcu‐
lation in the efficiency tracing of absolute activity measurement and patient- and technologist-
related risks for nuclear medicine imaging including Positron Emission Tomography (PET),
Computed Tomography (CT), PET/CT, and Single Photon Emission Computed Tomogra‐
phy (SPECT) were identified.
2. Quality system design based on the Requirements and Guidelines
2.1. Quality policy and system
The quality system by design for radiopharmaceuticals and clinical imaging techniques is
aimed to maintain and improve the qualified service for the patients, fulfill the regulatory
requirements, optimize the safety and efficacy for patient care, demonstrate a proper equip‐
ment operating condition, and obtain a reliable quantitative performance in both diagnos‐
tic and therapeutic nuclear medicine procedures [4,5]. The pursuit of excellence in quality
system is not a single action over a short period, instead, it is achieved through the whole
life cycle of instruments, analytical methods or education for example, from planning and
procurement to decommissioning based on advanced technology [6].  Continuous quality
improvement implies a commitment to continuously struggle to advance based on state-of-
the-art information and techniques developed by the nuclear medicine and metrology com‐
munity at large [5].
Implementation  of  a  quality  system must  be  in  accordance  with  the  quality  police,  i.e.
the overall  quality intentions and direction of an organization, as formally expressed by
top management.  And quality system includes the structure,  responsibilities,  and proce‐
dures for implementing quality management. An integrated infrastructure of quality pol‐
icy and system design is  demonstrated as in Figure 1,  which is  mainly developed from
the European Standard EN 28402 proposed by Bergmann et  al.  [7].  The attributes of the
components  in  the  quality  sub-system  (QA/QC),  e.g.  organization,  personnel,  facilities,
instrumentation, operation procedures, preparation of radiopharmaceuticals, protocol and
conduct, records and reports, and audit or inspection, were further integrated and classi‐
fied in this article.
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Figure 1. Quality policy and system for the radiopharmaceuticals [7].
2.2. Quality plan and key factors
2.2.1. Organization
The organization of quality system could be grouped into two categories: (a) synthesis and
preparation of nuclear medicine and (b) clinical imaging as shown in Figure 2 [8-10]. For
synthesis and preparation of nuclear medicine, three important guidelines were considered
[11-13]. Basically, preparation of “classical” radiopharmaceuticals in “kit” procedures and in
a “distinct chemical” procedures for PET radiopharmaceuticals are distinguished as two dif‐
ferent parts [11].
For the clinical imaging, the major differences PET and SPECT in QbD are related to the
properties and applications of a radiotracer. The most commonly used nuclides for PET
imaging, such as carbon-11, oxygen-15, nitrogen-13, and fluorine-18, exhibit shorter half-life
and more complicated labelling technology than that for SPECT imaging (Table 1)[14-31].
For example, the short half-lives of radionuclides used in PET modality allow for better de‐
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tection sensitivity over a given period of time. This is because radiotracers with shorter half-
lives can be injected in higher activities to the patient without posing any additional
radiation damage to the patient (since overall accumulation over time remains the same)
leading to the increased detectable radiation over a shorter time. Moreover, arguments that
the natural occurrence of PET isotopes in biologically active molecules (as opposed to heavy
isotopes used in SPECT) results in a less challenging task of synthesizing physiologically
useful tracers in PET modality [32,33]. In general, PET generally has a higher resolution,
higher sensitivity, and a better quantitation capability than SPECT. However, SPECT is
more practical as a routine procedure [18] and is more cost-effective for the system setting or
maintain than a PET facility [8].






C-11 20.4 min C-11-raclopride D2/D3 dopamine receptor
C-11-MADAM Serotonin transporter
N-13 9.96 min N-13-ammonia Blood flow (ventricle)
O-15 2.07 min 0-15 water Myocardium perfusion, brain
perfusion
Ga-68 68 min Ga-68-DOTA Neuroendocrine tumours
Latest Research into Quality Control258
F-18 109.8 min F-18-fallypride D2/D3 dopamine receptor
F-18-FDG Oncology imaging, metabolism of
glucose in tumors, brain and
myocardium
F-18-NaF Osseous metastasis
Cu-64 12.7 h Cu-64-ATSM Tumor hypoxia
I-124 4.12 d I-124-FIAU HSV1-tk expresssion
I-124-HMFGI (IgG1) Breast ductal carcinoma
SPECT imaging
agents






Tc-99m-Annexin-V Acute myocardial infarction,
chemotherapy response







Tc-99m sulfur colloid Lymph nodes
SPECT imaging
agents
I-123 13 hr I-123-Iomazenil Benzodiazepine (γ-aminobutyric
acid) receptor
I-123-IBZM D2/D3 dopamine receptor
I-123-iodobenzofuran D2/D3 dopamine receptor





In-111 2.8 d In-111-Zevalin Non-Hodgkin’s lymphoma





Tl-201 3.04 d Tl-201 Myocardium perfusion
Ga-67 3.3 d Ga-67 citrate Non-Hodgkin’s lymphoma
Therapy
agents
Sm-153 1.95 d Sm-153 EDTMP Metastatic bone pain palliation
Sr-89 50.5 d SrCl2 Palliative treatment of bone
cancers and for prostate cancer
P-32 14.28 d Orthophosphate Metastatic bone pain palliation
Re-186 3.78 d Re-186-HEDP Metastatic bone pain palliation
Re-188 17 h Re-188-bisphosphonate Metastatic bone pain palliation
Y-90 64.14 h Y-90 Ibritumomab
Tiuxetan
B-cell non-Hodgkin's lymphoma
I-131 8 d I-131 Tositumomab B-cell non-Hodgkin's lymphoma
Lu-177 6.7 d Lu-177-DOTA-Tyr3-
Octreotate
Small cell lung cancer
Ho-166 1.1 d Ho-166-DOTMP Multiple myeloma
Sn-117m 13.6 d Sn-117m-DTPA Metastatic bone pain palliation
At-211 7.2 h At-211-81C6 Glioblastoma multiforme tumors
Table 1. Some examples of radiopharmaceutical classification and applications [14-31]. ADAM: 2-((2-
((dimethylamino)-methyl) phenyl)thio)-5- iodophenylamine; DTPA: diethylenetriaminepentaacetic acid; ECD: ethyl
cysteinate dimer; FDG: fluoro-deoxy-glucose; FIAU: 1-(2-fluoro-2-deoxy-ß-D-arabinofuranosyl)-5-[I-124]iodouracil; FP-
β-CIT: N-propyl-2-beta-carboxy-methoxy-3-beta(4-iodophenyl)-nortropane; HMPAO: hexamethyl propylene amine
oxime; IBZM: iodobenzamide.
2.2.2. Staffing and personnel
Facilities should have written staff and personnel responsibilities and requirements. Two
types of staff in the requirements for synthesis and preparation of nuclear medicine and
clinical imaging are necessary [4]:
a. Personnel for synthesis and preparation of nuclear medicine may include such as facili‐
ty management, administrative staff, study director (SD), principal investigator (PI),
production chemists, QA manager or quality assurance unit (QAU), radiochemists, QC
chemists, cyclotron operators, and technologists.
b. Personnel for PET and SPECT imaging examination may include such as facility man‐
agement, administrative staff, medical physicists, nurses, referring physicians, nuclear
medicine physicians, radiopharmacist, radiochemists, radiation protection฀ officer, en‐
gineers, QA manager or QAU, and technologists.
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Figure 3. Quality system of staffing and personnel [9,34,35].
The responsibilities for staffing and personnel in a quality system are classified in Figure 3
[9,34,35] and briefly introduced below [4,6,7,36-38]:
a. Facility management: ensure the requirements, guidelines, and practices are complied
within facility, sufficient qualified personnel, appropriate facilities, equipment, and ma‐
terials are available, ensure that personnel clearly understand the functions they are to
perform and appropriate and technically valid Standard Operating Procedures (SOPs)
are established and followed, ensure that there is a QA manager or QAU with designat‐
ed personnel and their responsibility is being performed, ensure that for each study an
individual with the appropriate qualifications, training, and experience is designated by
the management as the SD and PI, ensure that an individual is identified as responsible
for the management of the archive.
b. Administrative staff: represent the first encounter a patient has with the centre. They re‐
ceive the patients according to the established protocols. In collaboration with the medi‐
cal and technical staff, they are responsible of the application of the procedures for
scheduling studies.
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c. SD and PI: they are responsible for approving, conducting, documenting, recording and
archiving the overall of the study and for its final report.
d. Nuclear medicine physicians: responsible for quality encompasses the general services
of the centre. In particular, supervises all patient care and management procedures and
all clinical protocols. In addition, he/she supports and enforces the QA/QC of equip‐
ment, establish clinical review and auditing.
e. QA manager or QAU: all those planned and systematic actions necessary to provide ad‐
equate confidence that a product or service will satisfy given requirements for quality,
express the closeness with which the outcome of a given procedure approaches some
ideal, free from all errors and artefacts. Quality assurance embraces all efforts made to
this end.
f. Radiopharmacist  and  Radiochemists  (Nuclear  pharmacy):  they  are  responsible  for
compounding,  dispensing,  quality  assessment,  patient  monitoring,  drug use review,
new drug  development  and evaluation,  product  selection  and performance  evalua‐
tion, pharmacokinetic modeling, drug information and educational services. They are
also responsible for the performance of acceptance testing and organization/supervi‐
sion  of  routine  calibration  and QC of  all  radiopharmacy  equipment;  QC of  chemi‐
cals,  enriched materials,  precursors,  and kits;  QC of  radiopharmaceuticals  products
and batch release.
g. Cyclotron operators: they are in charge of the daily operations, take part in the accept‐
ance test of the cyclotron and related equipment, and are responsible for calibration and
QC procedures for equipment.
h. Production chemists: synthesis and preparation of nuclear medicine.
i. QC chemists:  the restriction of QC persons is independent of the production opera‐
tions or must have independent oversight of these duties. The operational techniques
and activities that are used to fulfill  requirements for quality and are used in refer‐
ence to the specific measures taken to ensure that one particular aspect of the proce‐
dure is satisfactory.
j. Medical physicists:  specialized in nuclear medicine and responsible for the perform‐
ance  of  acceptance  testing  and  organization/supervision  of  routine  calibration  and
QC  of  imaging  and  radiation  measurement  equipment,  including  radiation  protec‐
tion instrumentation.
k. Radiation protection officer: ensure the radiation safety for patient, staffing, and environ‐
mental.
l. Engineers and Technologists: contribute to the preparation of clinical examination pro‐
tocols and the performance of patient examinations according to the established proto‐
cols, involved in the performance of routine calibration and QC of scanners.
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m. Nurses: manage and care of the patient, collaborate in preparing protocols of patient
management and information material as well as in checking the operation of other in‐
stitutional services.
In IAEA, quality manager is responsible for the entire quality management system supervi‐
sion, the authority to enforce it and act on its findings, and should be involved in the evalua‐
tion and periodic review of the results [5,6]. But, in EANM, the responsibility for overseeing
the preparation operations of a qualified radiopharmaceutical is called QAU [11,12].
2.2.3. Facility
In a PET facility, it should include the facility for (a) PET/CT scanner, (b) cyclotron, and (c)
radiopharmacy. The location of the facility is a very important issue for the flow of patients,
materials, and radiation protection. According to the risk of radiation exposure, two areas
are planned [4]:
a. low risk area, cold area or uncontrolled area is the area of offices, reception, waiting
room, consulting room, cleaning utilities room or store, and
b. high risk area, hot area or controlled area is the area of hot laboratory, preparation, in‐
jection and uptake room, toilet, control and scanning room, post-examination waiting
room, reporting room, and waste disposal room.
Figure 4. Quality system of facilities [34].
More considerations for the requirements of radiation protection and cleanliness are sum‐
marized in Figure 4 [34].
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2.2.4. Instrumentation and equipment
The instrumentation and equipment in the quality system are summarized in Figure 5
[34,38]. Apparatus and equipment for the purposes of manufacturing QC, diagnosis, and
therapy, including validated computerized systems, used for the generation, storage and re‐
trieval of data, and for controlling environmental factors relevant to the study should be
suitably located and of appropriate design and adequate capacity. Apparatus used in a
study should be periodically inspected, cleaned, maintained, and calibrated according to
SOPs. Records of these activities should be maintained. Calibration should be traceable to
national or international standards of measurement [39].
Figure 5. Quality system of instrumentation and equipment [34,38].
Performance tests and operation verification for the nuclear medicine units are achieved dai‐
ly, weekly, monthly, quarterly, or annually by a qualified medical physicist, a qualified nu‐
clear medicine technologist, or a medical physicist in training, with management by a
qualified medical physicist. The tests results of intrinsic or system spatial resolution, uni‐
formity, center of rotation, sensitivity, energy resolution, counting rate parameters, multi‐
ple-window spatial registration, formatter and video display, linearity, leak test, overall
system performance for imaging systems, interlocks, dose calibrators, thyroid uptake and
counting systems must be reviewed and documented in an annual survey report in accord‐
ance with the ACR Technical Standard for Medical Nuclear Physics Performance Monitor‐
ing of Nuclear Medicine Imaging Equipment [37].
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2.2.5. Operation procedures
A test facility should have written SOPs approved by facility management for ensuring the
quality and integrity of the data generation. Deviations from SOPs related to the manufac‐
turing, study, or treatment should be documented and should be acknowledged by the
study director, the principal investigator, the medical physician, quality assurance personnel
and/or radiopharmacist. The historical file of different version of all SOPs should be well re‐
corded and stored. The requirements of SOPs for nuclear medicine manufacturing and
imaging are summarized in Figures 6 and 7 [11,12,40-44].
Figure 6. Quality system of clinical operation procedures for nuclear medicine [11,12,40].
2.2.6. Radiopharmaceuticals
(a) Manufacturing of radiopharmaceuticals
Manufacturing and quality control plans for radiopharmaceuticals are indicated in Figure 8
[34,40,45]. Radiopharmaceuticals might be manufactured or prepared in hospital radiophar‐
macies, centralized radiopharmacies, nuclear centers, institutes, industrial manufacturers, or
PET centers in accordance with the requirements of good manufacturing practices (GMP) or
Current Good Radiopharmacy Practice (cGRPP) [11-13,34].
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Two categories of radiopharmaceuticals are classified in EANM Radiopharmacy Committee
according to the significant difference of preparation procedures, i.e. “kit” and PET radio‐
pharmaceuticals. Also, significant consideration in the “Guidelines on Current Good Radio‐
pharmacy Practice (cGRPP) in the Preparation of Radiopharmaceuticals” is proposed by
EANM Radiopharmacy Committee. Two types of preparation methods, i.e. in “classical”
procedure and in “synthetical” procedure, have been distinguished in cGRPP [11]. Accord‐
ing to WHO guideline, radiopharmaceuticals are divided into four categories including
ready-to-use, radionuclide generators, “kits” for the labelled with a radioactive component,
and precursors used for radiolabelling other substances before administration (e.g. samples
from patients) [13].
Figure 7. Quality system of clinical operation procedures for imaging [41-44].
Clinical investigations of radiopharmaceuticals can be approved by FDA as “legend drugs.”
The investigational radiopharmaceutical drug service (IRDS) is responsible for establishing
study-specific procedures for radiopharmaceutical drug, including preparation, storage, dis‐
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pensing and destruction of investigational drugs within the hospital [9]. Manufacturing or
preparation of radiopharmaceuticals must follow the FDA 21CFR Part 212 “Current Good
Manufacturing (cGMP) for PET drugs,” USP Chapter <797> “Pharmaceutical Compound‐
ing-Sterile Preparations,” USP Chapter <823> “Radiopharmaceuticals for Positron Emission
Tomography - Compounding,” and U.S. FDA Guidance: PET Drugs - Current Good Manu‐
facturing Practice (CGMP) [10].
(b) Quality control of radiopharmaceuticals
Three essential parts i.e. chemical, inventory, and radiochemical QC diagrams for radio‐
pharmaceuticals are also indicated in Figure 8 [30,50,45].
Figure 8. Quality system for radiopharmaceutical manufacturing and quality control [34,40,45].
Method developments  for  the  chemical  and radiochemical  analysis  of  starting  material,
intermediates, precursor used for the radiolabelling, active pharmaceutical ingredient (APIs
or drug substance), and finished product (drug product or finished dosage form) are essen‐
tial  requirements of  Chemistry,  and Manufacturing and Controls (CMC).  In the applica‐
tions of investigational new drug (IND), New Drug Application (NDA), and Abbreviated
New Drug Application (ANDA), information on the CMC has to be filed as per 21 CFR
312.23(a) for a drug substance and drug product. The contents for the CMC sections of the
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EU and U.S. are very much the same. However, the sequence and titles of the sections are
quite different [46,47].
According to International Conference on Harmonization (ICH) guidelines, the parameters
for the validation of analytical methods should basically include specificity (selectivity), lin‐
earity, precision (repeatability, reproducibility and intermediate), accuracy, recovery, limit
of detection (LOD), limit of quantification (LOQ), robustness, and stability. However, instru‐
ment validation parameters for the radioactivity measurement or isotopic analysis, such as
dose calibrator or liquid scintillation spectrometry, are partially different.
Radiopharmaceuticals are usually used before all quality control testing has been complet‐
ed. The implementation of and compliance with the quality assurance program are therefore
essential. Principal responsibilities of QA/QC are detailed by WHO and De vos et al., includ‐
ing preparation of detailed instructions for each test and analysis, ensuring the adequate
identification, ensuring equipment and process validation, release or rejection of materials,
evaluation of the quality and stability of the finished products, expiry dates, storage condi‐
tions, control procedures, specifications, and records keeping [13,34].
2.2.7. Protocol and conduct
Protocol for a medicine manufacturing study or imaging examination should be evaluated
according to the purposes of a study, a treatment, or a clinical trial. Safety issue, such as al‐
gorithm proposed by ASNC for maximal benefit in patient radiation exposure must be in‐
cluded [33].
For each study and treatment, a written plan or protocol should exist prior to the initiation
of the study. The protocol should be approved by dated signature of the study director,
principal investigator or medical physician, facility management, sponsor and verified by
quality assurance personnel and/or radiopharmacist. The study and treatment should be
conducted in accordance with the study plan or protocol by using a unique identification to
each study.
Clinical protocol should be evaluated based on the patient characteristics (e.g. patient histo‐
ry of disease or ability to complete the examination) and complexity of clinical situation in
accordance with the current statements and guidelines [33]. For instance, advantages and
disadvantages of assessing myocardial perfusion with PET, as compared to SPECT imag‐
ing, was reported and concluded that use of very short half-life tracers injected at very high
activities, as well as the introduction of increasingly fast scintillators technology, which in
turn has allowed reduction of random coincidences and introduced the possibility of time-
of-flight (TOF) PET are expected to further contribute to high sensitivity imaging capabili‐
ties of PET [32].
An example for approving of protocol design for a clinical trial is shown in Figure. 9 [10,47].
Two pathways for the clinical studies of investigational radiopharmaceuticals are called Ra‐
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dioactive Drug Research Committee (RDRC) and IND. For an investigational medical prod‐
uct (IMP, investigation only), if there are adequate data from literature or original
assessments that no pharmacologic effects are likely in humans, and the chosen radioactivity
is small enough to result in the total radiation absorbed dose, clinical trial can be approved
by National Competent Authority (NCA) and Ethical Committee (EC) in EU or approved by
RDRC in U.S.. Otherwise, it is approved by EC in EU or approved by FDA in U.S., depend‐
ing on the phase of drug development [47].
The FDA allows certain unique applications by the local RDRC, consisting of at least five
individuals and three individual specialists in nuclear medicine, in formulate radioactive
drugs, and in radiation safety, to approve and monitor for the use of radiopharmaceuticals
in humans without IND approval. This is due to the low potential for toxicity of radiophar‐
maceuticals that are typically administered in tracer quantities. Requirements to establish a
local RDRC at one’s institution is outlined in regulation 21 CFR 361.1. And RDRC has to
submit an annual report to the FDA as part of the procedures for maintaining an active and
approved RDRC program [48].
Figure 9. Quality system of protocol and conduct for a study or a treatment [10,47].
2.2.8. Records and reports
Records and reports for the manufacturing of radiopharmaceuticals and imaging trial or
testing are summarized in Figure 10 [7,9,40-44]. All records and reports should be main‐
tained at the radiopharmaceutical laboratory or another location that is accessible to respon‐
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sible officials and to government employees designated to perform inspections [11,12].
Storage of records must ensure safekeeping for many years. Archive facilities of independ‐
ent locations should be provided for the secure storage and retrieval of study plans, raw da‐
ta, final reports, samples of test items and specimens. Archive conditions, e.g. fireproof,
waterproof, and insect prevention are designed for protecting contents from untimely dete‐
rioration [38].
Figure 10. Quality system of records and reports [7,9,40-44].
2.2.9. Audit framework
Laboratory inspections and study audits should be established for periodical monitoring
compliance with GLP, GCP, or GMP principles, study protocol, and SOPs [9,38]. Audits for
radiopharmaceutical drug products typically begin by confirming the clinical site is appro‐
priately licensed and authorized to receive, possess, store, handle, prepare and administer
radiopharmaceuticals. The audit framework of quality system for radiopharmaceuticals,
imaging equipment, laboratory equipment, safety, computer systems, data handling, and ra‐
diation protection are displayed in Figure 11 [9,39].
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Figure 11. Quality system of audit framework. Audit (a) for radiopharmaceuticals manufacturing, and (b) for imaging
equipment, laboratory equipment, safety, computer systems, data handling, and radiation protection. [9,39]
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3. Quality evaluation and sources of uncertainty
3.1. Radiopharmaceuticals
3.1.1. Standardization: principle and applications
Quality control for the quantification of radiopharmaceutical activity is critical for accurate
dosimetry calculations, from whole body to cell microscopy. Tumor uptake of radiopharma‐
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1. Ge-68 EC decay to
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by LS)
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electrons plus L X-
rays and K X-rays
- U: 1% 53
Cs-134 β- and γ decay
to Ba-134
LSC ε: ~95% 3191 ± 8 kBq/g
(0.54%)
54
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4πβ-γ coincidence
method
ε: 65-87% 3194 ± 12 kBq/g
(0.88%)
4πγ method ε: ~83% 3174 ± 25 kBq/g
(2.09%)
C/N method





γ ray (167.4 keV)
probability: 0.1000
± 0.0006
7.207 ± 0.033 (NIST)
7.197 ± 0.027 (NPL)















εβ: 71 - 91%
εEC (~ εAEs): 50 -
100%
UC: 0.76% 57












Table 2. Some examples of absolute standardization of radiopharmaceuicals and related radioisotopes [17,50-58]
The theoretical counting efficiency, i.e. counts/disintegration or counts per minute/disinte‐
gration per minute (cpm/dpm), for a radionuclide can be used to examine the absolute activ‐
ity, in disintegration or disintegration per minute (dpm) of the radionuclide. Different
efficiency tracing methods has been developed for more than six decade by characterizing
the effects of sample volume, medium composition (matrix), pulse discrimination condi‐
tions, photomultiplier voltage, amplifier gain, and luminophor concentration on counting
efficiency of a radioactive species [49]. The use of 4πβ scintillation counting and 4πβ-γ coin‐
cidence counting for the standardization of certain electron capture (EC) nuclides with sim‐
ple decay schemes is established since 1952 [49] and 1957 [50].
Some examples of absolute standardization of radiopharmaceuicals and related radioiso‐
topes are shown in Table 2 [17,50-58]. Below, we introduce different tracing methods, in‐
cluding (a) efficiency tracing (and extrapolation) method using a non-H-3 standard solution,
(b) CIEMAT-NIST (C/N) efficiency tracing method, (c) non-extrapolation tracer method, (d)
coincidence method by a 4πβ-γ system, (e) triple to double coincidence ratio (TDCR) meth‐
od, and (f) 4πγ counting method.
(a) The efficiency tracing (and extrapolation) method using a non-H-3 standard solution
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The efficiency tracer techniques, using Co-60, Cs-134, C-14, Cr-51, Mn-54 or Am-241 stand‐
ard solution for the standardization of the β-γ nucides were developed. The 4π liquid scin‐
tillation (LS) consisted of the extrapolation of the 4π counting rate to the zero discrimination
level for the standardization of the Tl-204 (97.6% β emission and 2.4% electron capture) solu‐
tion was carried out for efficiency tracing using a Co-60 standard solution received in the
framework of the 1997 BIPM comparison was carried out by Sahagia et al. [59]. A germani‐
um spectrometer was calibrated for the standardization of Pb-210 using Am-241 as a nor‐
malizing agent has been proposed [58]. Instead, Dias et al. chose Cs-134 as an efficiency
tracer to standardize Tl-204 as well as a 4πβ-γ coincidence system for the calibration [57].
This method can be also successfully used for the standardization of radionuclides such as
Ir-192, Zn-65, Mn-54, with the detection of the β rays, Auger electrons, X rays, in the propor‐
tional counter (PC) [60]. Efficiency tracing with C-14 and zero detection threshold techni‐
ques with H-3 as tracers was applied for standardization of various β-emitting
radionuclides, e.g. C-14, Cl-36, and Tl-204 using LS spectrometer [61].
Recently, different methodologies were proposed. Koskinas et al. developed a “dual-trac‐
ers”, e.g. Cr-51 and Mn-54 procedure followed by the Laboratório de Metrologia Nuclear
(LMN) for the standardization of EC nuclide, i.e. Fe-55. The efficiency was obtained by se‐
lecting a γ-ray window set at 320 keV (Cr-51) and at 834 keV (Mn-54) [62]. The activity of EC
radionuclides is usually determined by 4π (proportional counter, PC)-γ coincidence count‐
ing and by an efficiency extrapolation method. However, an alternative method, called “wet
extrapolation method”, utilizes an absorption change during the drying of a water droplet
added onto the source surface, variation of the PC detection efficiency can be achieved.
Slopes of extrapolation curves and resulting activity values obtained are compared for sev‐
eral radionuclides (Mn-54, Ce-139, Y-88, and Co-57) [63].
(b) The CIEMAT-NIST (C/N) efficiency tracing method
CIEMAT/NIST (C/N) method, developed by Centro de Investigationes Energéticas, Medio‐
ambientales y Tecnologicas (CIEMAT), Spain and the National Institute of Standards and
Technology (NIST), U.S. is used for standardization of radionuclides with Liquid Scintilla‐
tion (LS) Spectrometry by calculating the counting efficiency of the radionuclide to be as‐
sayed and using H-3 as a tracer [61]. C/N program is suitable used for the calculation of the
efficiency of nuclides decayed by β, β-γ, EC, EC-γ and nuclides with mixed decay [51]. The
basic principle of C/N LS efficiency tracing method is a combination of a theoretical calcula‐
tion of the counting efficiency and an experimental determination of correction factors in
three steps [61,64]:
• Count rates (cpm) and the quench-indicating parameters (QIPs, i.e. tSIE) are determined
for a set of samples of the nuclide to be measured, and for a set of H-3 standard samples,
with a different quench. The tSIE values were calculated using the Ba-133 source inside of
the instrument. By combining these data, a corresponding H-3 efficiency is obtained for
each sample of the nuclide.
• The universal curve of Figure of Merit (FOM) as a function of tSIE was plotted. The effi‐
ciency of the nuclide is theoretically calculated as a function of the efficiency of the tracer
nuclide H-3.
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• This relation is used in conjunction with the measured data to calculate the efficiency for
the nuclide and an activity value in dpm for each single measurement.
The parameters of emitters in different decay modes used for the C/N calculations are sum‐
marized as follows [51]:
• Pure β emitters (Sr-89, Sr-90, Y-90, and K-40): atomic number Z of the radionuclide, the
mass number A, the endpoint energy EMax, and the shape parameters.
• Pure γ emitters (Nb-93m): the efficiency is nearly 100%.
• β+γ emitters, if the radionuclide has significant levels with half-lives in the order of the
coincidence resolving time or the dead time of the equipment, a C/N calculation is not
possible.
• Pure EC emitters: the input parameters are the capture probabilities, PK; PL; PM, and the
atomic parameters for the rearrangement: the fluorescence yields ωK and ωL (averaged),
the probabilities of the X-rays (PKL, PKX, and PLX) and their average energies (EKL,
EKX, and ELX), the emission probabilities of the Auger electrons (PKLL, PKLX, PKXY,
and PLXY) and their average energies (EKLL, EKLX, EKXY, and ELXY).
• EC+γ emitters (Co-57, Se-75, Sr-85, and Ba-133): the calculation method is the same as for
β+γ nuclides.
• The efficiency of LSC systems with respect to alpha radiation is in each case very close to
unity. A tracer method is not necessary.
(c) The non-extrapolation tracer method
An alternative called “non-extrapolation tracer method” was proposed by Steyn et al. in
1979, where Fe-55 was used as a tracer to establish the figure-of-merit (FOM) of the detec‐
tion system for the calculation of counting efficiency [65]. The liquid scintillation method,
for the determination of absolute activity of Mn-54 and Zn-65 from 4π(LS)e-γ data by direct
calculation without efficiency extrapolation was performed. The non-extrapolation LS meth‐
od relies on determining the probability of the γ-ray interacting with the scintillator solu‐
tion, is described and validated by measurements made on Co-60 [66].
(d) The coincidence method by a 4πβ-γ system
Coincidence method comes from the additional coincidence channel, which records a disin‐
tegration event when it is detected in both β- and γ-channels. Typically, the system for abso‐
lute standardization is usually consisted of a gas-flow or pressurized proportional counter
with 4π geometry as the α, β, electrons or X-ray detector and coupled to a pair of NaI(Tl)
scintillation counters or a semiconductor detector, as γ detectors. The 4πβ-γ coincidence
technique has been considered a primary standardization method due to its high accuracy
and because it can obtain the radionuclide activity depending only on observables quantities
[57,67].
Alternatively, solid or liquid scintillation counters (LSC) are used in place of gas-flow pro‐
portional counters. Advantages of using LSC counting in the 4π channel are that self-ab‐
sorption does not occur, leading to Auger electrons being detected with relatively high
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efficiency; source preparation is easy; and the source geometry is highly reproducible. The
latter leads to good reproducibility of the counting efficiency of the X-rays and Auger elec‐
trons, which in turn gives rise to consistent results amongst the counting sources. The effi‐
ciency data can generally be fitted with a linear function, particularly in the high-efficiency
region, or by a low-order polynomial expression, giving rise to reliable extrapolated activity
values [68].
Several examples for the applications of the coincidence method by a 4πβ-γ system are such
as standardization of Ho-166m using the normal gas flow 4πβ-γ coincidence method [69],
standardization of Tl-204 using Cs-134 as tracer and a 4πβ-γ coincidence system was used
for the calibration [57], directly measured of radionuclides with EC decay schemes, e.g.
I-125, Ir-192, Zn-65, and Ce-139 by a LS coincidence extrapolation technique [68], and stand‐
ardization of Fe-55 using a “dual-tracers” method coupled with a 4πβ-γ coincidence calibra‐
tion system [62].
(e) The triple to double coincidence ratio (TDCR) method
The TDCR method was first developed at the R.C., Poland and at the LNHB, France. The
equipment consists in a detection unit, provided with three photomultipliers (PMs), acted
by the light emitted in the vial containing the radioactive solution dissolved in a liquid scin‐
tillator, and the electronic unit [60]. TDCR, allowing the observation of three kind of double
coincidences (2-photodetectors) and triple coincidence (3-photodetectors) method in LSC, is
a fundamental measurement method suitable to the standardization of pure-beta emitters,
i.e. H-3, C-14, P-32, Ni-63, Tc-99, Tl-204 and some low energy electron-capture emitters, i.e.
Fe-55 [59,60,70,71]. Detection efficiency variation can be achieved using techniques of chemi‐
cal quenching, coaxial grey filters and PM tubes defocusing. The two former processes re‐
duce the mean quantity of light emitted and the later reduces the detection probability [71].
Basically, the specific experimental parameter (K) is equal to the ratio of the triple coinciden‐
ces counting rate (NT) to the sum of double coincidences counting rate (ND). Determination
of a counting efficiency (εD) for each counting point (ND) leads to the activity of the source
(N0). The efficiency functions εT and εD are nonlinear functions for a particular emitter and
counting system [70].
Two innovative TDCR instrumentations were developed:
• The TDCR method of LSC is well established for measuring the activity of pure beta emit‐
ting and electron capture radionuclides. Recently, a new TDCR counting system was de‐
signed by the National Physical Laboratory (NPL) for activity assays of low-energy, pure
β-emitting radionuclides and EC nuclides. Three photomultiplier tubes (PMT) were ar‐
ranged in the optical chamber as well as a NaI(Tl) detector was mounted below the opti‐
cal chamber. The detector allows 4πβ-γ coincidence measurements to be performed in
parallel [72].
• Radionuclides such as P-32, Sr-89, Y-90, Tl-204, and Rh-106 were successfully studied us‐
ing an in-house built new TDCR-Čerenkov counter developed by Kossert. Since Čerenkov
counting acts as natural discrimination for αemitters and low-energy β emitters, some po‐
tential radioactive impurities or progenies will not disturb the measurements. Two stand‐
ard sources, e.g. Cl-36 and P-32 were used to determine the free parameter and to
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calculate the Čerenkov counting efficiencies. Since Čerenkov counting is more sensitive to
changes in the computed β spectra, the method was extensively used to investigate β
shape factor functions [73].
(f) The 4πγ counting method.
An ionization chamber system referring to a long living and stable standard source is very
adequate for the comparison of γ-ray emitting radio-nuclides. In most cases Ra-226 sealed
sources have been used as the reference because the Ra-226 sources were widely used in ra‐
diotherapy [69]. Zimmerman et al. standardized and compared solution of Sn-117m by 4πβ
liquid scintillation (LS) spectrometry and 4π γ-ray spectrometry (NaI(Tl) and high-purity
germanium detectors). Massic activities were measured for determining the dose calibrator
factor settings [17].
3.1.2. Uncertainty of measurement
Examples  for  the  evaluation  of  detection  efficiency  (ε),  activity  accuracy,  and  measure‐
ment uncertainty (U) of absolute activity of radiopharmaceuicals and related radioisotopes
are shown in Table 2. Components of combined uncertainty were further summarized in
this section.
(a) Uncertainty for the efficiency tracing (and extrapolation) method using a non-H-3 stand‐
ard solution
Components of combined uncertainty in the activity determination include counting statis‐
tics, background, dead time, weighing, decay scheme parameter, half-life, and extrapolation
of efficiency curve [57].  Source of uncertainty evaluated by Woods et al.  in the absolute
standardization of low energy β emitter, i.e. Pb-210 are counting, background, half life, β dead
time, γ dead time, resolving times, choice of fit, count rate dependence, dead time formula,
weighing, separation time, extrapolation range, contaminants, and reproducibility [58].
(b) Uncertainty for the C/N efficiency tracing method
Component of uncertainty in the standardization of Re-186 by the C/N method of LS effi‐
ciency tracing with H-3 include source preparation, scintillator stability, dead time, liquid-
scintillation measurements, uncertainty due to H-3 reference standard, EC/β- branching
ratio, spectral distributions for EC and β- branches. [74]
The contributions to the uncertainty of the value of the specific activity are volatility of H2
[GeCl6] during the preparation of solid sources for coincidence measurements, drop mass‐
es, counting statistics, background variation, accidental coincidences and dead time losses,
Compton continuum of the 1077 keV peak included in the γ window around the 511 keV peak,
decay scheme correct ion factor, correction factor for non-vanishing εEC, impurities and half-
life uncertainty, and detection of 511 keV quanta in the β detector due to its γ sensitivity [52].
The components contributing to the uncertainty of 4πβ-γ coincidence method were estimat‐
ed as follows: counting statistics and background variation, instrumental corrections, impur‐
ities, half-life uncertainty, decay scheme correction factor, and mass of droplet. Standard
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deviation of LSC composed of the following contributions: counting statistics, background
variation, scintillator stability, comparison with H-3 tracer, instrumental corrections (dead
time), dilution factor, droplet mass, radioactive impurities, half-life uncertainty, main decay
data, uncertainty of the ε calculation due to the K-L model, capture probabilities PK, PL, fluo‐
rescence yields, ωK, ωL, spectral distribution of β particles, and average energy of weak Aug‐
er electrons [75].
Source of the uncertainty: counting statistics, mass, dead time, background, timing, chemi‐
cal effects (adsorption, sample spread, impurities), input parameters and statistical model,
quenching, kB influence, decay scheme parameters, and pulse shape discriminator setting. [76]
(c) Uncertainty for the non-extrapolation tracer method
The quoted total uncertainty (1σ) of 0.85% comprised mainly the components due to count‐
ing statistics (0.28%), afterpulsing (0.40%) and the evaluated decay-scheme data (0.63%). εM:
double tube detection efficiency of Mn-54, εM*: reduced Mn-54 efficiency due to quenching
caused by the addition of the Fe-55 aliquot [65].
(d) Uncertainty for the coincidence method by a 4πβ-γ system
Uncertainty components assayed by Koskinas et al. for the standardization of Eu-152 were
counting statistics, weighing, dead time, impurities, half life, extrapolation of efficiency
curve [77].
(e) Uncertainty for the TDCR method
The main source of uncertainty of TDCR method comes from the model describing the non-
linearity of the scintillator due to the ionization quenching phenomenon [71]. Type A stand‐
ard uncertainty, i.e. counting statistics and type B standard uncertainty, i.e. extrapolation
(interception uncertainty), spurious pulses, nonuniformity of sources, tracer activity, E. C.
correction, dead-time, background, half-life, weighing were evaluated by Sahagia et al. [59].
(f) Uncertainty for the 4πγ counting method.
Construction of an ionization chamber efficiency curve is not a straightforward process as
the curve has to be extracted from experimental calibration points analytically. The efficien‐
cy curve is implicitly contained in individual radionuclide coefficients and these are ob‐
tained experimentally or by Monte Carlo modelling or calculated back from the efficiency
curve. Due to this variety, the interpretation and intercomparison of different efficiency
curves is often hard and transferring individual radionuclide calibration coefficients be‐
tween ionization chambers of different constructions is not a simple process [78].
3.1.3. International measurement program
One of the most important components in the quality system of radiopharmaceuticals is to
establish the measurement traceability to international standards for ensuring the accurate
and consistent of measurement results [5]. Traceability of activity measurements is the criti‐
cal part in the production and use of unsealed radioactive sources in nuclear medicine. The
U.S. Nuclear Regulatory Commission (NRC) defines a medical event as a patient receiving
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an injected activity greater than 20% different from the prescribed dosage. Tthe Society of
Nuclear Medicine (SNM) guidelines also recommend that the measurement be with 10% of
the prescribed dosage. Moreover, the instruments being used are capable of accurate meas‐
urements to within 5% [79]. Therefore, programs for the establishment and dissemination of
activity measurement standards in nuclear medicine are held in many countries.
International comparison of standard sources and solutions, such as P-32, Mn-54, Zn-65,
Ir-192, Tl-204, and Am-241, which is organized by the International Committee of Weights
and Measures (CIPM), the EUROMET system, the former COMECOM, and bilateral com‐
parisons, has been held since 1962 [60].
South Africa’s national radioactivity measurement standard is maintained by the National
Metrology Laboratory (NML) of the Council for Scientific and Industrial Research (CSIR).
Standardizations are undertaken by a number of direct methods utilizing liquid scintillation
counting (LSC) [80].
Comparisons of activity measurements for I-131, Tl-201 and Tc-99m with radionuclide cali‐
brators were organized in Cuba since 2002. During 2002, the Radionuclide Metrology De‐
partment of the Isotope Center (CENTIS-DMR) has organized several comparisons with
various radionuclides in order to obtain information on the quality of the activity measure‐
ments during production and administration of radiopharmaceuticals in Cuba [81].
The Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) conducts a series
of Radiopharmaceutical Quality Assurance Test Program under a Memorandum of Under‐
standing (MOU) between ARPANSA and the Therapeutic Goods Administration (TGA). For
example, in 2005, 46 batches of 24 different types of radiopharmaceuticals, e.g., ready to use
radiopharmaceuticals and kits for the preparation of Tc-99m were tested. Two percent in 46
batches of radiopharmaceuticals tested was failure to meet full specifications [82].
International comparison program of national metrological institutes for the standardization
of Fe-55, which is a suitable radionuclide standard for X-ray spectrometers, was held by the
Comité Consultative pour les Etalons de Mesures des Rayonnements Ionisants (CCEMRI) of
the Bureau International des Poids et Mesures (BIPM) [62]. National Metrology Institute of
Japan - Advanced Industrial Science and Technology (NMIJ/AIST, Japan) and National In‐
stitute of Ionizing Radiation Metrology (ENEA-INMRI, Italy) have been involved in recent
years, particularly those relevant in the frame of the international cooperation coordinated
by the BIPM and the International Committee for Radionuclide Metrology (ICRM). Particu‐
lar research activities are devoted on the field of the nuclear safety, nuclear medicine and
environmental radionuclide measurements. [83]. International comparisons held by BIPM
also can be traced by laboratories such as National Institute for Physics and Nuclear Engi‐
neering (Romania) [59], Laboratorio de Metrologia Nuclear (Brazil) in collaboration with the
Laboratório Nacional de Metrologia das Radiações Ionizantes, from Rio de Janeiro [57], Ra‐
diation Safety Systems Division, Bhabha Atomic Research Centre (India) [61], and Electro‐
technical Laboratory (ETL) (Japan) [69].
The Ce-139 measurements formed part of a regional comparison organized by the Asia Pa‐
cific Metrology Programme (APMP) [68].
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The National Institute of Standards and Technology (NIST) maintains a program for the
establishment and dissemination of activity measurement standards in nuclear medicine, i.e.
Ga-67, Y-90, Tc-99m, Mo-99, In-111, I-125, I-131, and Tl-201 for more than ten years. These
standards are disseminated through Standard Reference Materials (SRMs), Calibration Serv‐
ices, radionuclide calibrator settings, and the NIST Radioactivity Measurement Assurance
Program (NRMAP, formerly the NEI/NIST MAP). For over 3600 comparisons, 96% of the
participants’ results differed from that of NIST by less than 10%, with 98% being less than 20%.
The percentage of participants results within 10% of NIST ranges from 88% to 98% [79].
Measurements from a variety of types of detectors including, ionization chambers, radionu‐
clide calibrators, solid state detectors, Ge detectors, NaI(Tl) detectors, liquid scintillation
counters (LSC), Cherenkov counting, and proportional counter are reported [79].
3.2. Nuclear medicine imaging
3.2.1. PET, CT, PET/CT, and SPECT imaging
PET, CT, PET/CT, and SPECT are non-invasive imaging tools and applied for creating two
dimensional (2D) cross section images of three dimensional (3D) objects. PET and SPECT
can potentially provide functional or biochemical information by measuring distribution
and kinetics of radiolabelled molecules, whereas CT visualizes X-ray density in tissues in
the body. The PET imaging in oncology has been migrating from the use of dedicated PET
scanners to the use of PET/CT tomographs. This is due to the advantages that PET/CT offers
over dedicated PET. One of these advantages is that the integration of PET and CT imaging
into a single scanning session allows excellent fusion of the acquired data. Although these
nuclear medicine imaging tools provide many advantages and applications in diagnosing
diseases clinically, they also poses some challenges and induce artifacts and quantitative er‐
rors that can affect the image quality.
3.2.2. Risks of artifact in PET, CT, and SPECT imaging
Artifacts and pitfalls can arise at any stage in the process of nuclear medicine imaging and
can be grouped into issues related to the (i) patient, (ii) the equipment, or the technologist.
(a) Patient-related risks:
In PET/CT, the patient-related artifacts commonly found are due to metallic implants, trun‐
cation, and respiratory motion (or patient motion). These artifacts occur because the CT scan
is used to replace a PET transmission scan for the purpose of attenuation correction of the
PET data.
Metallic  implants,  such as  dental  fillings,  hip  prosthetics,  or  chemotherapy ports,  cause
high CT numbers and generate streaking artifacts  on CT images due to their  high pho‐
ton absorption [85,86]. This increase CT numbers causes correspondingly high PET attenu‐
ation coefficients, resulting in an overestimation of the PET activity and thereby to a false-
positive PET finding.
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In PET/CT, truncation artifacts occur due to the difference in size of the field of view be‐
tween the CT (50 cm) and PET (70 cm) tomographs [87,88] and frequently seen in large pa‐
tients or patients scanned with arms down, such as in the case of melanoma and head and
neck indications. When a patient extends beyond the CT field of view, the extended part of
the anatomy is truncated and consequently is not represented in the reconstructed CT im‐
age. Truncation also causes streaking artifacts at the edge of the CT image, leading to an
overestimation of the attenuation coefficients used to correct the PET data. This increase in
attenuation coefficients creates a rim of high activity at the truncation edge, resulting in the
misinterpretation of the PET scan.
The most prevalent artifact in PET/CT imaging is respiratory motion during scanning. The
artifact is due to the discrepancy between the chest position on the CT image and the chest
position on the PET image. PET images are acquired over time periods (time frames) that
can vary from a few seconds to tens of minutes. Therefore, during such time periods various
motions may have significant effects on the PET images. Both respiratory and contraction
induced heart motions have major effect (source of error) on PET imaging of cardiac and
thoracic regions. Some equipment, e.g., dose calibrators for the measurements of quantita‐
tive measurements is calibrated against or traceable to a reference source of whole body to‐
mographs [89]. Because of the long acquisition time of a PET scan, it is acquired while the
patient is freely breathing. The final image is hence an average of many breathing cycles. On
the other hand, a CT scan is usually acquired during a specific stage of the breathing cycle.
This difference in respiratory motion between PET scans and CT scans results in breathing
artifacts on PET/CT images. Several literatures have described this problem [90-91]. The arti‐
facts resulted from respiratory motion or patient motion is also commonly found in myocar‐
dial perfusion SPECT. This is because that SPECT requires that the object of interest remains
constant for the duration of the acquisition [92-93]. Visually detectable patient motion has
been reported in 36% of clinical studies in one study [94] and 43% in another [95].
Source of clinical problems of the patients were also indicated by Hladik III, including (i)
special patient populations, e.g., pregnant or breast-feeding women, pediatric and geriatric
patients, patients requiring dialysis, incontinent, catheterized or miscellaneous patients, (ii)
insufficient patient care, education, and preparation, e.g. insufficient patient instruction,
shielding or protection in exposure and contamination problems, pregnancy testing, with‐
holding xanthine-containing foods and drug-drug interaction prior to imaging, delay in the
administration or imaging, metal implants of patient, (iii) improper behavior of patient, e.g.,
excessive movement, contamination from incontinence, attenuation from jewelry, prosthe‐
ses, or implants, etc., and (iv) unexpected altered biodistributions may be undetectable, ad‐
verse reactions or untoward effects, [96]
(b) Equipment- or technologist-related risks:
There are several patient-related artifacts and interpretation pitfalls that can potentially
compromise nuclear medicine imaging, as discussed above. In order to minimize or identify
these artifacts, technologists play an important role in recognizing and correcting them. For
example, technologists should ask patients to remove all metallic objects before imaging and
should document the location of non-removable metallic objects to minimize or identify the
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artifacts from metallic implants. In PET/CT imaging, it is crucial for technologists to careful‐
ly position patients at the center of the field of view and with arms above head to reduce
truncation artifacts. Moreover, in order to minimize the artifacts from respiratory motion
and produce accurately quantifiable images, it is also essential that technologists instruct pa‐
tients about breath-hold techniques before the scanning session.
Moreover, sources of clinical problems of error medication also include fail of (i) patient
identification, (ii) dosage prescription and administration, (iii) radionuclide administration,
(iv) radiopharmaceutical prescription and administration in kinetics or finished product pu‐
rity testing, (v) interventional medications, (vi) injection technique, (vii) radiopharmaceuti‐
cal labelled, (viii) preparation or execution of diagnostic or therapeutic procedure, and (ix)
radiation protection [7,96].
QC performed on nuclear medicine cameras provides the confidence to technologists and
physicians that a scan supplies an accurate representation of the radioisotope distribution in
the patient. The instrumentation for nuclear medicine imaging is more complex than that
used for whole-body and planar imaging, and requires careful quality control to ensure op‐
timum performance. According to the standards, the main performance parameters are div‐
ided into two groups. The first group includes basic intrinsic measurements: spatial
resolution in axial and transaxial directions, sensitivity, count rate capabilities by measuring
the system dead time and the generation of random events at different radioactivity levels,
and scatter fraction of γ rays emitted by the annihilation of positron. The second group in‐
cludes measurements of the accuracy of corrections for physical effects, specifically: uni‐
formity correction, scatter correction, attenuation correction, and count rate linearity
correction. Other possible tests to be added to the list of acceptance or performance tests
such as: noise equivalent count rate, partial volume and spillover, motion artefacts, image
quality test, and PET/CT image co-registration [89].
Nuclear medicine imaging increases the accuracy of diagnosis by combining anatomic infor‐
mation with functional imaging. It is highly dependent on a host of technical considerations.
Knowledgeable technologists can minimize or reduce artifacts and other potential problems
with image acquisition and, in that way, produce better-quality images.
4. Conclusion
Implement of ICH QbD for the radiopharmaceutical manufacturing and imaging technology
can be harmonized to a globalized framework in accordance with the regulations and re‐
quirements of U.S. FDA, IAEA, WHO and EANM. The attributes of the components in the
quality unit (QA/QC), including the aspects of organization, staffing and personnel, facili‐
ties, instrumentation and equipment, operation procedure, radiopharmaceuticals, protocol
and conduct of a study or a treatment, records and reports, and audit were reviewed and
indentified. Critical quality attributes (CQAs) for assuring accurate radioactive dosimetry
calculation in the efficiency tracing of absolute activity measurement and in the patient- and
technologist-related risks for nuclear medicine imaging (PET, CT, and SPECT), i.e. potential
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sources of error or uncertainty, were elucidated. Although there still have many hard-to-
controlled quantitative errors and artifacts that can eventually affect the quality of imaging,
therapeutic efficacy, or safety, it is important for the facility staffs to be aware and continual
improvement of these quality factors. By reducing uncertainty and risk or increasing process
knowledge and product understanding resulting from QbD can significantly improve the ef‐
ficiency of manufacturing processes.
5. Abbreviations
API Active pharmaceutical ingredient
ARPANSA Australian Radiation Protection and Nuclear Safety Agency
BNMS British Nuclear Medicine Society
BIPM Bureau International des Poids et Mesures (France)
CT Computed Tomography
CFR Code of Federal Regulations (U.S.)
CMC Chemistry, and manufacturing and controls
CQAs Critical quality attributes
CSIR Council for Scientific and Industrial Research
CGMP Current Good Manufacturing Practice
CGRPP Current Good Radiopharmacy Practice (EU)
EC Ethical Committee (EU)
EANM European Association of Nuclear Medicine (EU)
EDQM European Directorate for the Quality of Medicines & HealthCare
EIND Exploratory IND (FDA, U.S.)
FDA U.S. Food and Drug Administration
HPLC High-performance liquid chromatography
ICH International Conference on Harmonisation
IMP Investigational Medicinal Product (for drugs used in clinical trials of EU)
IND Investigational new drug
IAEA International Atomic Energy Agency
IRDS Investigational Radiopharmaceutical Drug Service
LSC Liquid scintillation counting
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MA Marketing authorization (EU)
MS Mass spectrometry
MOU Memorandum of Understanding
NRC Nuclear Regulatory Commission
NCA National Competent Authority (EU)
PET Positron emission tomography
QA Quality assurance
QC Quality control
QP Qualified persons who are professional responsible for the release of a drug in Europe
QbD Qulaity by design
RPR Responsible person for the small-scale preparation of radiopharmaceuticals
RDRC Radioactive Drug Research Committee (FDA, U.S.)
SPECT Single photon emission computed tomography
SSRP Small-scale “in-house” radiopharmaceutical
SOP Standard operating procedure
TGA Therapeutic Goods Administration
TLC Thin layer chromatography
USP United States Pharmacopeia
WHO World Health Organization
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